Cedergrenska AB (”Cedergrenska” eller ”Koncernen”) presenterade den 12 maj 2025 preliminära siffror ...
Stabilt, stabilare, EQL Pharma Nettoomsättningen ökade med imponerande 45,0 %, främst drivet av tidi...
Redeye provides a brief comment following Alzinova’s announcement of the outcome of its SEK35.
Nettoomsättningen uppgick till 204,6 MSEK (199,3), vilket motsvarade en ökning med 2,7% y-o-y.
Redeye provides its initial take on Acarix’s Q1 report, which showed growth in both revenue and inst...
Redeye thinks the new positive MAD results from CAN10 further support the case.
Redeye provides its initial view on Kontigo Care’s Q1 2025 results, which came in slightly below exp...
During the weekend, Sprint Bioscience announced that the US firm Day One has decided to discontinue ...
Group net sales was EUR 28.4m in Q1 (Nordea EUR 28.
Digging into the feasibility study and mineral resource update Feasibility study arrives an NPV of S...
Redeye provides a research update following IRLAB's Q1 report.
Redeye provides a research update following Catella’s Q1 2025 report.
CapMan posted a solid set of Q1 numbers, with fee income growing 8% y/y, roughly in line with our ex...
Q1e: top line and adj. EBITDA +14% and 9% y-o-y '25e-'27e sales down 3%, limited adj.
Obducat (”Obducat” eller ”Bolaget”) publicerade den 9 maj 2025 Bolagets delårsrapport för det första...
- Investments in sales held back margins in Q1... - .
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har publicerat Koncernens delår...
Fastighetsbolaget Trianon har inlett 2025 med en miljardförsäljning av fastigheter till storägaren B...
Redeye is optimistic about Alligator’s completion of GMP production of mitazalimab, a precondition f...
